Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.

MLA

Asshoff, Malte, et al. “Momelotinib Inhibits ACVR1/ALK2, Decreases Hepcidin Production, and Ameliorates Anemia of Chronic Disease in Rodents.” Blood, vol. 129, no. 13, Mar. 2017, pp. 1823–30. EBSCOhost, https://doi.org/10.1182/blood-2016-09-740092.

APA

Asshoff, M., Petzer, V., Warr, M. R., Haschka, D., Tymoszuk, P., Demetz, E., Seifert, M., Posch, W., Nairz, M., Maciejewski, P., Fowles, P., Burns, C. J., Smith, G., Wagner, K.-U., Weiss, G., Whitney, J. A., & Theurl, I. (2017). Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood, 129(13), 1823–1830. https://doi.org/10.1182/blood-2016-09-740092

Chicago

Asshoff, Malte, Verena Petzer, Matthew R Warr, David Haschka, Piotr Tymoszuk, Egon Demetz, Markus Seifert, et al. 2017. “Momelotinib Inhibits ACVR1/ALK2, Decreases Hepcidin Production, and Ameliorates Anemia of Chronic Disease in Rodents.” Blood 129 (13): 1823–30. doi:10.1182/blood-2016-09-740092.